{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$6.15 vs. cons $5.84",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA net of NCI",
      "prediction": "BEAT",
      "answer": "pred ~$675M vs. cons $633M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$4.63B vs. cons $4.56B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$23.50 vs. cons $23.70 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EBITDA net of NCI guidance",
      "prediction": "LOWER",
      "answer": "guide ~$2.70B vs. cons $2.73B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue guidance",
      "prediction": "BETTER",
      "answer": "guide ~$18.75B vs. cons $18.69B (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Exchange-related pretax headwind",
      "prediction": "LOWER",
      "answer": "guide ~$140M headwind vs. cons $110M headwind (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Florida Medicaid supplemental-payment benefit",
      "prediction": "BETTER",
      "answer": "guide ~$90M benefit vs. cons $75M benefit (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.8,
  "day5_path": "FADE",
  "day5_rationale": "Predicted day-5 residual of ~+0.8% versus day-1 residual of ~+2.8%: the headline beat and Florida benefit initially support the stock, but a larger exchange headwind and FY2026 EPS/EBITDA guidance below consensus limit positive revisions and cause most of the initial gain to fade.",
  "day5_confidence": "MEDIUM"
}